Fennec real-world data show PEDMARK safe in adults with head & neck cancers, no disruption to cisplatin therapy

FENNEC PHARMACEUTICALS INC.

Data from retrospective review of 15 adult HNC patients presented at 2026 MHNCS symposium (Feb 19-21).
PEDMARK given ≥6 hours after cisplatin was feasible and well tolerated; no grade 3/4 toxicities observed.
Majority of high-risk patients had no measurable hearing loss during or after treatment despite baseline impairment.
No disruption to curative-intent cisplatin-based treatment delivery was noted in the study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.